Frontiers in Cardiovascular Medicine · Nov 16, 2026
Cardioprotective Interventions During Anthracycline-Based Chemotherapy: A Systematic Review and Network Meta-Analysis
By Linxuan Luo, Huan Wu, Yi Xiang et al.
Objective: To evaluate efficacy signals of cardioprotective interventions in adults receiving anthracycline-based chemotherapy and assess the certainty and clinical interpretability of the evidence. Methods: PubMed, the Cochrane Library, Web of Science, and Embase were searched from inception through October 22, 2026, for randomized controlled trials. Bayesian random-effects analyses evaluated final left ventricular ejection fraction (LVEF), change in LVEF, definition-specific cardiotoxicity, global longitudinal strain (GLS) change, and natriuretic peptide changes. BNP and NT-proBNP were analyzed separately. Risk of bias, confidence in the evidence, and sensitivity to study exclusion and treatment classification were assessed. Results: Fifty-eight reports representing 59 independent trials were included. Compared with Control, final LVEF was higher with spironolactone (mean difference [MD] 12.08 percentage points, 95% credible interval [CrI] 3.57–20.65) and enalapril (MD 6.64, 95% CrI 0.57–12.80). Lower odds of LVEF-defined cardiotoxicity were estimated for atorvastatin, enalapril, and a cardioprotective diet intervention. In the supplementary pairwise analysis, dexrazoxane was associated with lower odds of composite cardiac events (odds ratio 0.31, 95% CrI 0.16–0.59), although its prediction interval included the null. All treatment-versus-Control CrIs included zero for changes in LVEF, GLS, BNP, and NT-proBNP. Important estimates were sensitive to individual trials or sample-size restrictions. Overall confidence was very low for network comparisons with completed ratings; certainty for the dexrazoxane composite-event comparison was low. Conclusion: Selected interventions showed outcome-specific efficacy signals, but sparse evidence, uncertainty, and limited robustness precluded a reliable treatment hierarchy. These findings identify priorities for further randomized trials rather than establish comparative recommendations for clinical drug selection. Comparative safety and net clinical benefit remain undetermined.